Skip to Content

Vitrasert Implant

Active Substance: ganciclovir
Common Name: ganciclovir
ATC Code: J05AB06
Marketing Authorisation Holder: Dr. Gerhard Mann, Chem.-Pharm. Fabrik GmbH..
Active Substance: ganciclovir
Status: Withdrawn
Authorisation Date: 1997-03-18
Therapeutic Area: Cytomegalovirus Retinitis HIV Infections
Pharmacotherapeutic Group: Antivirals for systemic use

Therapeutic Indication

The Vitrasert implant is indicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) (See 4.4. Special warnings and special precautions for use).

The marketing authorisation for Vitrasert Implant has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.